IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy

INTRODUCTION: Factor IX replacement therapy is used for treatment and prophylaxis of bleeding in haemophilia B. rIX‐FP is an extended half‐life albumin‐fusion protein, which, in clinical studies, has demonstrated prolonged dosing intervals up to 21 days for routine prophylaxis, providing therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Tagliaferri, Annarita, Molinari, Angelo Claudio, Peyvandi, Flora, Coppola, Antonio, Demartis, Francesco, Biasoli, Chiara, Borchiellini, Alessandra, Cultrera, Dorina, De Cristofaro, Raimondo, Daniele, Filomena, Giordano, Paola, Marchesini, Emanuela, Margaglione, Maurizio, Marino, Renato, Pollio, Berardino, Radossi, Paolo, Santoro, Cristina, Santoro, Rita Carlotta, Siragusa, Sergio, Sottilotta, Gianluca, Tosetto, Alberto, Piscitelli, Lydia, Villa, Maria Rosaria, Zanon, Ezio, Finardi, Adele, Schiavetti, Irene, Vaccari, Daniella, Castaman, Giancarlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099489/
https://www.ncbi.nlm.nih.gov/pubmed/36423202
http://dx.doi.org/10.1111/hae.14689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099489/
https://www.ncbi.nlm.nih.gov/pubmed/36423202
http://dx.doi.org/10.1111/hae.14689

Ejemplares similares